The document outlines an action plan for the health sector response to HIV in Europe with the vision of ending the AIDS epidemic as a public health threat by 2030. It identifies five strategic directions: (1) using data to guide focused services, (2) prioritizing prevention and treatment interventions, (3) delivering equitable services based on human rights, (4) financing a sustainable response, and (5) stimulating innovation. Fast-track actions are outlined under each strategic direction to strengthen coordination, expand testing and treatment, eliminate transmission, and transition to domestic financing. The draft resolution calls on countries to review strategies, strengthen prevention, ensure commitment and financing, and monitor implementation of the plan.
Strategic directions for the health sector response to viral hepatitis include:
1) Improving surveillance and estimates of disease burden to focus action.
2) Defining essential intervention packages and setting national targets for coverage.
3) Addressing barriers like stigma to make hepatitis services accessible for all populations.
4) Building political commitment and innovative funding approaches for sustainable financing.
5) Prioritizing hepatitis research and rapidly translating findings into practice.
The action plan aims to halt transmission of hepatitis and ensure treatment access for all by 2030.
The WHO Health Emergencies Programme in the European Region focuses on several priority areas:
1) Country health emergency preparedness and International Health Regulations core capacity building.
2) Health emergency information and risk assessment through 24/7 monitoring and early detection of public health events.
3) Emergency operations management for graded health emergencies and coordination of partner responses.
4) Infectious hazard management including prevention and control strategies for high-threat pathogens.
The Programme operates through core services and is working to ensure countries have the capacities for all-hazards health emergency risk management.
Presented by Dr Piroska Östlin, Director and Dr Santino Severoni, Coordinator, Public Health and Migration, Division of Policy and Governance for Health and Well-being, WHO/Europe, at the 66th session of the WHO Regional Committee for Europe.
Presented by Dr Gauden Galea, Director, and Dr Gunta Lazdane, Programme Manager, Noncommunicable Diseases and Promoting Health through the Life-course, WHO/Europe, at the 66th session of the WHO Regional Committee for Europe.
Presented by Piroska Östlin, Director and Åsa Nihlén, Technical Officer, Division of Policy and Governance for Health and Well-being, WHO/Europe, at the 66th session of the WHO Regional Committee for Europe.
Dr Caroline Brown, Programme Manager, Influenza and Other Respiratory Pathogens, Thomas Hofmann, IHR Area Coordinator, Communicable Diseases and Health Security
Presentation by Dr Zsuzsanna Jakab,WHO Regional Director for Europe, at the Third High-level Meeting of the Small Countries Initiative, in Monaco, on 11–12 October 2016
Strategic directions for the health sector response to viral hepatitis include:
1) Improving surveillance and estimates of disease burden to focus action.
2) Defining essential intervention packages and setting national targets for coverage.
3) Addressing barriers like stigma to make hepatitis services accessible for all populations.
4) Building political commitment and innovative funding approaches for sustainable financing.
5) Prioritizing hepatitis research and rapidly translating findings into practice.
The action plan aims to halt transmission of hepatitis and ensure treatment access for all by 2030.
The WHO Health Emergencies Programme in the European Region focuses on several priority areas:
1) Country health emergency preparedness and International Health Regulations core capacity building.
2) Health emergency information and risk assessment through 24/7 monitoring and early detection of public health events.
3) Emergency operations management for graded health emergencies and coordination of partner responses.
4) Infectious hazard management including prevention and control strategies for high-threat pathogens.
The Programme operates through core services and is working to ensure countries have the capacities for all-hazards health emergency risk management.
Presented by Dr Piroska Östlin, Director and Dr Santino Severoni, Coordinator, Public Health and Migration, Division of Policy and Governance for Health and Well-being, WHO/Europe, at the 66th session of the WHO Regional Committee for Europe.
Presented by Dr Gauden Galea, Director, and Dr Gunta Lazdane, Programme Manager, Noncommunicable Diseases and Promoting Health through the Life-course, WHO/Europe, at the 66th session of the WHO Regional Committee for Europe.
Presented by Piroska Östlin, Director and Åsa Nihlén, Technical Officer, Division of Policy and Governance for Health and Well-being, WHO/Europe, at the 66th session of the WHO Regional Committee for Europe.
Dr Caroline Brown, Programme Manager, Influenza and Other Respiratory Pathogens, Thomas Hofmann, IHR Area Coordinator, Communicable Diseases and Health Security
Presentation by Dr Zsuzsanna Jakab,WHO Regional Director for Europe, at the Third High-level Meeting of the Small Countries Initiative, in Monaco, on 11–12 October 2016
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the School of Public Health Management (Chisinau, Republic of Moldova, 24 November 2016)
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the 21st Congress of the European Association of Dental Public Health (1 October 2016 Budapest)
This document summarizes a presentation on health in Europe and priorities for the future. It discusses increasing life expectancy and healthy life years across the region. However, there remain discrepancies between countries. Priorities include achieving universal health coverage, tackling non-communicable and communicable diseases, strengthening health systems, addressing social and environmental determinants of health, and improving emergency preparedness. Investing in public health through policies like tobacco control provides high economic returns. Accelerating progress on disease prevention, immunization, viral hepatitis and antimicrobial resistance is needed.
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the 67th session of the WHO Regional Committee for Europe (Budapest, Hungary, 11–14 September 2017)
Contemporary health policy context in Europe: some opportunities and challenges
Presentation by Dr Zsuzsanna Jakab, WHO Regional Director for Europe. 8 March 2017, Israel
The document summarizes epidemiological data on tuberculosis (TB) in Italy and globally. It notes that the TB notification rate in Italy decreased by 7.7% from 2007 to 2012. In 2012, 58.3% of Italian TB cases were in foreign-born individuals and the rate of multi-drug resistant TB was 3%. Globally in 2012, there were an estimated 8.6 million incident TB cases and 1.3 million deaths, with South-East Asia and Africa accounting for most cases and deaths. Major ongoing challenges include TB/HIV co-infection, multi-drug resistant TB, and improving detection of "missing" TB cases.
This presentation is part of the report presented by the WHO Regional Director Zsuzsanna Jakab at the 63rd session of the WHO Regional Committee for Europe in Çeşme Izmir, Turkey, on 16 September 2013.
Dr Zsuzsanna Jakab, WHO Regional Director for Europe,Policy Dialogue on Health System and Public Health Reform in Cyprus: Health in the 21st Century, 26–27 September 2017, Nicosia, Cyprus
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe (Positioning the Veneto Region at the core of global and European health policies, 3-4 December 2015, Scuola San Giovanni Evangelista, Venice, Italy)
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the 7th Meeting of the European Advisory Committee on Health Research (Copenhagen, Denmark, 6 April 2016)
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: John F. Ryan, Director, European Commission, DG SANTE
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
This document discusses ensuring continuity of essential health services during the COVID-19 pandemic, which is a critical priority. It outlines the impact of the pandemic on essential health services, including disruptions to services for noncommunicable diseases and declines in immunization rates. It also discusses challenges delivered essential health services during the pandemic, such as limitations in health system capacity and shortages of supplies. The document provides an overview of WHO's guidance and activities to support delivering essential health services during COVID-19, and innovative approaches that have been used. It calls for renewed commitment to achieving universal health coverage and the Sustainable Development Goals.
1. The director of the EMCDDA discussed the evolution of HIV, drugs, and risk behavior in Europe based on lessons learned over decades. New HIV infections attributed to injecting drug use have declined significantly since the 1990s due to effective drug treatment and prevention programs.
2. However, regional disparities remain, and new outbreaks have been linked to stimulant use and new psychoactive substances. Maintaining prevention services and reaching vulnerable groups who are not in care will be important to address ongoing challenges.
3. Going forward, the EMCDDA aims to maintain understanding of drug use trends, identify new health threats to support rapid responses, promote effective interventions, and support policy development - all to contribute to
This document summarizes resolutions and decisions from various World Health Assembly and Executive Board meetings that are of regional concern. Key topics discussed include strategies for HIV, viral hepatitis, STIs, food safety, epilepsy, non-communicable diseases, harmful use of alcohol, social determinants of health, and sustainable financing. The regional office will support member states in implementing frameworks, strategies, and plans on these issues through regional consultations, capacity building, and technical guidance. Progress on non-communicable diseases and neurological disorders in particular falls short of targets in most member states in the region.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Annette Verster, WHO
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Д-р Florence FUCHS, Штаб-квартира ВОЗ - Шестьдесят пятая сессия Европейского регионального комитета ВОЗ (Вильнюс, Литва, 14–17 сентября 2015 г.) / Presentation delivered by Dr Florence Fuchs, WHO Headquarters, at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Presentation delivered by Tim Nguyen, Unit leader - Tanja Kuchenmüller, Technical Officer at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the School of Public Health Management (Chisinau, Republic of Moldova, 24 November 2016)
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the 21st Congress of the European Association of Dental Public Health (1 October 2016 Budapest)
This document summarizes a presentation on health in Europe and priorities for the future. It discusses increasing life expectancy and healthy life years across the region. However, there remain discrepancies between countries. Priorities include achieving universal health coverage, tackling non-communicable and communicable diseases, strengthening health systems, addressing social and environmental determinants of health, and improving emergency preparedness. Investing in public health through policies like tobacco control provides high economic returns. Accelerating progress on disease prevention, immunization, viral hepatitis and antimicrobial resistance is needed.
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the 67th session of the WHO Regional Committee for Europe (Budapest, Hungary, 11–14 September 2017)
Contemporary health policy context in Europe: some opportunities and challenges
Presentation by Dr Zsuzsanna Jakab, WHO Regional Director for Europe. 8 March 2017, Israel
The document summarizes epidemiological data on tuberculosis (TB) in Italy and globally. It notes that the TB notification rate in Italy decreased by 7.7% from 2007 to 2012. In 2012, 58.3% of Italian TB cases were in foreign-born individuals and the rate of multi-drug resistant TB was 3%. Globally in 2012, there were an estimated 8.6 million incident TB cases and 1.3 million deaths, with South-East Asia and Africa accounting for most cases and deaths. Major ongoing challenges include TB/HIV co-infection, multi-drug resistant TB, and improving detection of "missing" TB cases.
This presentation is part of the report presented by the WHO Regional Director Zsuzsanna Jakab at the 63rd session of the WHO Regional Committee for Europe in Çeşme Izmir, Turkey, on 16 September 2013.
Dr Zsuzsanna Jakab, WHO Regional Director for Europe,Policy Dialogue on Health System and Public Health Reform in Cyprus: Health in the 21st Century, 26–27 September 2017, Nicosia, Cyprus
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe (Positioning the Veneto Region at the core of global and European health policies, 3-4 December 2015, Scuola San Giovanni Evangelista, Venice, Italy)
Presentation delivered by Dr Zsuzsanna Jakab, WHO Regional Director for Europe, at the 7th Meeting of the European Advisory Committee on Health Research (Copenhagen, Denmark, 6 April 2016)
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: John F. Ryan, Director, European Commission, DG SANTE
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
This document discusses ensuring continuity of essential health services during the COVID-19 pandemic, which is a critical priority. It outlines the impact of the pandemic on essential health services, including disruptions to services for noncommunicable diseases and declines in immunization rates. It also discusses challenges delivered essential health services during the pandemic, such as limitations in health system capacity and shortages of supplies. The document provides an overview of WHO's guidance and activities to support delivering essential health services during COVID-19, and innovative approaches that have been used. It calls for renewed commitment to achieving universal health coverage and the Sustainable Development Goals.
1. The director of the EMCDDA discussed the evolution of HIV, drugs, and risk behavior in Europe based on lessons learned over decades. New HIV infections attributed to injecting drug use have declined significantly since the 1990s due to effective drug treatment and prevention programs.
2. However, regional disparities remain, and new outbreaks have been linked to stimulant use and new psychoactive substances. Maintaining prevention services and reaching vulnerable groups who are not in care will be important to address ongoing challenges.
3. Going forward, the EMCDDA aims to maintain understanding of drug use trends, identify new health threats to support rapid responses, promote effective interventions, and support policy development - all to contribute to
This document summarizes resolutions and decisions from various World Health Assembly and Executive Board meetings that are of regional concern. Key topics discussed include strategies for HIV, viral hepatitis, STIs, food safety, epilepsy, non-communicable diseases, harmful use of alcohol, social determinants of health, and sustainable financing. The regional office will support member states in implementing frameworks, strategies, and plans on these issues through regional consultations, capacity building, and technical guidance. Progress on non-communicable diseases and neurological disorders in particular falls short of targets in most member states in the region.
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: Annette Verster, WHO
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Д-р Florence FUCHS, Штаб-квартира ВОЗ - Шестьдесят пятая сессия Европейского регионального комитета ВОЗ (Вильнюс, Литва, 14–17 сентября 2015 г.) / Presentation delivered by Dr Florence Fuchs, WHO Headquarters, at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Presentation delivered by Tim Nguyen, Unit leader - Tanja Kuchenmüller, Technical Officer at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
Presentations delivered by Dr Nedret Emiroglu (Director, Division of Communicable Diseases and Health Security at the WHO Regional Office for Europe) - High-level meeting on refugee and migrant health (23-24 November 2015, Rome, Italy)
Presentation delivered by Claudia Stein, Director - Division of Information, Evidence, Research and Innovation at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
1. The WHO Regional Director for Europe launched the Knowledge Hub on Health and Migration, a multi-stakeholder platform for sharing knowledge and improving public policies around health needs of migrants.
2. An analysis of health indicators in Sicily found higher infant mortality, lower life expectancy, and social inequalities compared to other EU regions in Italy.
3. Reducing health inequities will require action on social, economic, and environmental determinants of health across the life course from early childhood through working years.
This document summarizes the WHO Draft Global Implementation Plan for the International Health Regulations (IHR) from 2005. The plan was requested by the World Health Assembly in 2016 and addresses recommendations from the IHR Review Committee. The draft plan proposes both immediate implementation of recommendations within the existing IHR framework, as well as areas that may require consultation or amendments. It includes 6 areas of action that encompass the committee's 12 major and 60 supporting recommendations. The areas focus on accelerating country implementation, strengthening WHO capacity, improving monitoring and reporting, improving risk assessment and communication, enhancing compliance with temporary recommendations, and rapid sharing of scientific information.
Dr Gauden Galea, Director, Noncommunicable Diseases and Promoting Health through the Life-course, WHO Regional Office for Europe - Dr Jo Inchley, HBSC International Coordinator, University of St Andrews
The document discusses the impacts of austerity measures on health and well-being in Europe. It notes that while life expectancy has increased 5 years on average, there are divides between countries. Financial crises threaten recent health gains and exacerbate challenges to health systems. Noncommunicable diseases like cardiovascular disease and cancer place a major burden. Investing in health promotion and disease prevention can help address this burden in a cost-effective manner. Maintaining social welfare spending and policies can help mitigate some of the negative health impacts of unemployment during an economic downturn.
The document summarizes the proposed WHO program budget for 2018-2019. Some key points:
- The budget structure and priorities are similar to 2016-2017, continuing existing commitments and building on regional and global priorities.
- New elements include a revised structure for the Health Emergencies Programme and incorporation of the Sustainable Development Goals.
- The total proposed budget is $4.66 billion, an increase of $319 million from 2016-2017. Major increases are for the Health Emergencies Programme, antimicrobial resistance, and polio eradication.
- Feedback will be incorporated before the budget is finalized and approved by the World Health Assembly in May 2017.
Dr Oleg Chestnov, помощник генерального директора
Dr Jill Farrington, и.о. руководителя офиса проекта по НИЗ в Москве
Dr Gauden Galea, директор
Отдел неинфекционных заболеваний и укрепления здоровья на всех этапах жизни
Presentation delivered by Claudia Stein, Director, Division of Information, Evidence, Research and Innovation, on 15 September 2015, at the 65th session of the WHO Regional Committee for Europe (Vilnius, Lithuania, 14–17 September 2015)
This document provides a summary of the work of the WHO Regional Office for Europe. It discusses progress made in several areas such as:
1) Declining inequalities in life expectancy across countries in the region.
2) Strengthening of policies by European countries to reduce tobacco and alcohol consumption and increase physical activity.
3) Successful control and prevention programs reducing communicable diseases like tuberculosis, measles, and malaria.
4) Efforts to strengthen health systems, promote universal health coverage, and develop a people-centered approach to healthcare delivery.
5) Work to improve emergency preparedness, surveillance of diseases, and response capacity to health emergencies and public health threats.
Presented at the 66th session of the WHO Regional Committee for Europe by Dr Claudia Stein, Director,
Information, Evidence, Research and Innovation, WHO/Europe
The document summarizes the Global Health Sector Strategy for HIV for 2011-2015. It was developed through an inclusive consultation process to align with broader strategic frameworks. The strategy reaffirms global goals for the health sector response to HIV and provides four strategic directions to guide national HIV responses. It aims to enhance effectiveness, ensure equity, and improve quality of HIV programs. The strategy outlines the global vision, goals, strategic directions, priority policies and interventions, and how WHO will support countries in implementing national HIV programs.
This document proposes a global hepatitis strategy to control and prevent viral hepatitis. It summarizes that hepatitis is a silent epidemic with a high death toll but low awareness. The strategy proposes impact targets by 2030 of reducing new chronic hepatitis B and C cases by 90% and reducing hepatitis deaths by 65%. It outlines key effective interventions such as hepatitis B vaccination, safe injection practices, harm reduction, and treatment. The proposed way forward is a regional action plan for WHO and tailored country actions based on disease burden analysis and focus on efficient investments.
Non-Communicable Diseases: Malaysia in Global Public HealthFeisul Mustapha
Paper presented at a CME Session, held in conjunction with the NIH Research Week 2014, 26 November 2014 at the Institute for Health Management, Bangsar
The document outlines the End TB Strategy developed by the World Health Organization to end the global tuberculosis epidemic. It discusses the burden of TB, progress made, and ongoing challenges. The strategy has three pillars: integrated patient-centered care and prevention, bold policies and supportive systems, and intensified research and innovation. It aims to reduce TB deaths and incidence rates through universal health coverage, new tools, and social protections to reach targets by 2025 and 2035. Progress will be measured using indicators like treatment coverage, success rates, and uptake of new diagnostics.
European approach - HA-REACT Joint Action as an exmple_engTHL
The HA-REACT Joint Action aims to improve prevention and treatment of HIV, HCV, and TB among people who inject drugs in the EU. It has several work packages focused on testing and linkage to care, scaling up harm reduction, improving continuity of care in prisons, and integrated care. Activities conducted so far include training healthcare workers, developing educational materials, assessing harm reduction needs in focus countries, and piloting new services like mobile outreach units and harm reduction programs in prisons. The goal is to build capacity and update national programs to better respond to the needs of people who inject drugs.
The document summarizes the WHO European Action Plan for the Prevention and Control of Noncommunicable Diseases 2016–2025. The plan aims to achieve reductions in premature mortality from noncommunicable diseases like cardiovascular disease, cancer, diabetes and chronic respiratory diseases. It outlines priority areas like governance, surveillance, prevention, health systems strengthening, and population-level policies. The plan is aligned with the global action plans and frameworks to address noncommunicable diseases.
Presentation made by Zsuzsanna Jakab, WHO Regional Director for Europe, at the meeting "Health in Action reforming the Greek National Health System to Improve Citizens’ Health", on 5 March 2014, Athens, Greece.
The document outlines a road map to accelerate HIV prevention efforts to meet global targets of reducing new HIV infections by 75% by 2020. It finds that while progress has been made, declines in new infections have been too slow, with only 1.7 million new infections in 2016, an 11% decline since 2010. Of 25 focus countries, only 3 saw over 30% declines, while 8 had no decline or increases. No country met the 2015 target of 50% reduction. Faster progress is needed to avoid increased treatment costs and continued mother-to-child transmission programs. The road map proposes intensified prevention programs, especially for adolescent girls, young women and key populations.
The National Health Policy 2017 aims to achieve universal health coverage and deliver quality health care services to all Indians. It sets targets to reduce mortality and disease burdens, and increase access to services by 2025. The policy shifts the focus from sick care to wellness, and outlines objectives to provide primary health care, improve access to secondary and tertiary care, and reduce out-of-pocket health expenditures. It also establishes principles, compares targets between the 2002 and 2017 policies, and details guidelines across several areas including health programs, human resources, regulation, and research.
Sustainability and transition - Nicolas Cantau, The Global FundOECD Governance
This presentation was made by Nicolas Cantau, The Global Fund, at the 2nd Health Systems Joint Network Meeting for Central, Eastern and Southeastern European Countries held in Tallinn, Estonia, on 1-2 December 2016
India has moved from a tuberculosis (TB) control program to eliminating TB through its National Strategic Plan for TB Elimination (2017-2025). Key challenges include engaging private providers, addressing drug-resistant TB, and preventing new TB cases. The plan aims to reduce TB incidence and mortality by 80% and 90% respectively by 2025. Strategies include engaging private providers, active case finding, addressing social determinants, and a multisectoral approach. The government's digital Nikshay program tracks TB cases and outcomes nationwide to support elimination goals.
Viral hepatitis Elimination challenges and progress Final.pptxDrHarsh Saxena
This document discusses viral hepatitis elimination challenges and progress. It notes that globally over 300 million people are living with viral hepatitis, making it the 2nd leading infectious disease killer. The WHO adopted a global strategy in 2016 to eliminate hepatitis by 2030 through vaccination, prevention of mother-to-child transmission, injection/blood safety, harm reduction, and testing/treatment. However, progress has been slow and more investment is needed, especially in low- and middle-income countries. The document then discusses India's hepatitis burden and its national action plan to combat viral hepatitis, with goals of eliminating hepatitis C by 2030 and reducing disease from hepatitis B and C.
This document discusses emerging infectious diseases and antimicrobial resistance as key issues for health governance in Europe. It provides information on progress made in several areas:
1) Establishing a WHO European action plan to address antimicrobial resistance that has been adopted by all 53 member states.
2) Expanding infectious disease surveillance networks to cover all member states.
3) Collecting region-wide data on antimicrobial use and consumption to support action by countries.
4) Adopting strategies in the European action plan for HIV/AIDS from 2012-2015 to reduce vulnerability and optimize prevention and treatment outcomes.
The annual report summarizes the National TB Program in Swaziland for 2012. Key highlights include: ART uptake among HIV+ TB patients increased to 66%; TB treatment success rate improved to 73% but remains below the 85% WHO target; MDR-TB cases increased from 332 to 613 from 2011 to 2012; and MDR-TB treatment success rate improved from 18% to 57%. The report outlines the program structure, services provided, epidemiological trends showing declining TB burden, and challenges around drug supply and MDR-TB recording and reporting. Recommendations focus on strengthening MDR-TB surveillance, drug supply chain management, research activities, and laboratory collaboration.
NCD Planning: Current Stats and Opportunities for StrokeFeisul Mustapha
The document discusses non-communicable diseases (NCDs) planning in Malaysia and opportunities for stroke prevention. It summarizes the 2014 UN General Assembly outcome document on NCDs which outlines national commitments and global assignments between 2014-2018. These include setting national NCD targets and developing multisectoral policies and plans. It also discusses Malaysia's national strategic plan for NCDs from 2010-2014 and efforts to strengthen chronic disease management at the primary care level through multidisciplinary care teams and clinical practice guidelines. Availability of essential medicines for NCDs and lessons learned from working with other sectors are also covered.
NACP IV aims to halt and reverse the HIV epidemic in India from 2014-2019. Key strategies include intensifying prevention services for high-risk groups, increasing access to comprehensive care and treatment, expanding IEC services, building program capacities, and strengthening strategic information management systems. The goal is to reduce new HIV infections by 50% from the 2007 baseline. Prevention efforts will focus on high-risk groups like female sex workers, while care, support and treatment will be expanded through more ART centers and linkage to health services.
Similar to Presentation –Action plan for the health sector response to HIV (20)
This document summarizes measles and rubella surveillance data from the WHO European Region from March 2021 to February 2022. It finds that 22 countries reported 222 measles cases, with the majority (87%) occurring in 10 countries including Tajikistan, Turkey, Belgium, and Poland. 107 rubella cases were reported by 12 countries, with 96 cases in 5 countries including Poland, Turkey, Ukraine, and Germany. The data also examines case trends over time and genotypes in an effort to monitor elimination goals for these vaccine-preventable diseases.
This document summarizes reported measles cases in the WHO European Region from March 2021 to February 2022. It shows the total number of measles cases and incidence rate per country over this period. The highest numbers of cases were reported in Poland, Germany, Italy, and Ukraine. Overall, there were 222 measles cases reported in March 2021, rising to a peak of 35 cases in October 2021, before declining to 33 cases in February 2022.
The document summarizes measles and rubella surveillance data from the WHO European Region. It provides data on measles and rubella cases, incidence, genotypes, and vaccination coverage from 2021-2022. The top countries for measles and rubella cases in this period are reported, with Turkey, Poland, and Ukraine among those with the highest numbers of measles cases and Poland reporting the most rubella cases.
The document provides an overview of measles and rubella cases and vaccination coverage in the WHO European Region from 2021-2022. It summarizes measles and rubella data for 2021, including the top 10 countries by cases. Turkey had the most measles cases in 2021 while Poland had the most rubella cases. Vaccination coverage for measles-containing vaccines was over 90% from 2010-2021.
The document summarizes measles and rubella surveillance data from the WHO European Region from December 2020 to November 2021. It finds that 148 measles cases were reported in this period, with the majority (89%) occurring in 11 countries including Turkey, France, Poland, and Belgium. 103 rubella cases were reported in the same period, with over 90% concentrated in 5 countries including Italy, Germany, Turkey, and Ukraine. Overall measles and rubella cases have declined in the region since 2018 but surveillance and vaccination efforts need to remain vigilant to prevent further outbreaks.
Reported measles cases for the period November 2020—October 2021 (data as of 02 December 2021).A monthly summary of the epidemiological data on selected vaccine-preventable diseases in the WHO European Region
The document summarizes measles and rubella surveillance data from the WHO European Region from October 2020 to September 2021. It finds that Turkey, Ukraine, and Poland reported the most measles cases, with Turkey reporting 35 cases. It also finds that Azerbaijan, Germany, Turkey, Ukraine, and Poland reported the most rubella cases, with Poland reporting 47 cases. Overall, measles and rubella cases have decreased in the region since 2019, but ongoing vaccination efforts are still needed to eliminate both diseases.
The document provides information on measles and rubella cases in the WHO European Region from September 2020 to August 2021. It summarizes that Turkey, Ukraine, and Poland reported the most measles cases, while Poland, Ukraine, and Turkey reported the most rubella cases. Overall measles and rubella cases have declined compared to previous years but outbreaks still occur periodically in some countries. The document also provides links to additional measles and rubella surveillance resources on the WHO website.
The document provides an overview of measles and rubella cases in the WHO European Region from August 2020 to July 2021. It summarizes measles and rubella data, including the number of reported cases by country, genotype information, and monthly trends over multiple years. Turkey had the highest number of measles cases while Poland had the most rubella cases. Measles cases were highest among unvaccinated children under 5 years old.
The document summarizes measles and rubella surveillance data from the WHO European Region from July 2020 to June 2021. It finds that for measles, Turkey, Ukraine, Belgium, Poland and France reported the most cases, with Turkey reporting 30 cases. For rubella, Italy, Turkey, Germany, Ukraine and Poland reported most of the 80 total cases. The number of measles cases decreased from 2020 to 2021 while the number of rubella cases remained low. Vaccination coverage and outbreaks varied by country.
The document provides measles and rubella surveillance data for the WHO European Region from May 2020 to April 2021. It shows that:
- Kazakhstan reported the highest number of measles cases, while Poland, France, and others also reported cases.
- For rubella, Poland reported the highest number of cases between May 2020 to April 2021, while Italy, Turkey, Germany and Ukraine also reported cases.
- Both measles and rubella cases were highest in 2020 compared to previous years, though rubella cases remained low overall, with 188 cases reported for 2020.
Uzbekistan and Kazakhstan reported the highest numbers of measles cases between April 2020-March 2021, with 446 and 423 cases respectively. Overall, 1,511 measles cases were reported in this period in the WHO European Region, with 96% occurring in the top 10 reporting countries. For rubella, 86 total cases were reported between April 2020-March 2021, with 97% found in the top 5 countries of Italy, Turkey, Germany, Ukraine, and Poland.
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)bkling
Your mindset is the way you make sense of the world around you. This lens influences the way you think, the way you feel, and how you might behave in certain situations. Let's talk about mindset myths that can get us into trouble and ways to cultivate a mindset to support your cancer survivorship in authentic ways. Let’s Talk About It!
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
Unlocking the Secrets to Safe Patient Handling.pdfLift Ability
Furthermore, the time constraints and workload in healthcare settings can make it challenging for caregivers to prioritise safe patient handling Australia practices, leading to shortcuts and increased risks.
Michigan HealthTech Market Map 2024. Includes 7 categories: Policy Makers, Academic Innovation Centers, Digital Health Providers, Healthcare Providers, Payers / Insurance, Device Companies, Life Science Companies, Innovation Accelerators. Developed by the Michigan-Israel Business Accelerator
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
Chandrima Spa Ajman is one of the leading Massage Center in Ajman, which is open 24 hours exclusively for men. Being one of the most affordable Spa in Ajman, we offer Body to Body massage, Kerala Massage, Malayali Massage, Indian Massage, Pakistani Massage Russian massage, Thai massage, Swedish massage, Hot Stone Massage, Deep Tissue Massage, and many more. Indulge in the ultimate massage experience and book your appointment today. We are confident that you will leave our Massage spa feeling refreshed, rejuvenated, and ready to take on the world.
Visit : https://massagespaajman.com/
Call : 052 987 1315
At Apollo Hospital, Lucknow, U.P., we provide specialized care for children experiencing dehydration and other symptoms. We also offer NICU & PICU Ambulance Facility Services. Consult our expert today for the best pediatric emergency care.
For More Details:
Map: https://cutt.ly/BwCeflYo
Name: Apollo Hospital
Address: Singar Nagar, LDA Colony, Lucknow, Uttar Pradesh 226012
Phone: 08429021957
Opening Hours: 24X7
R3 Stem Cell Therapy: A New Hope for Women with Ovarian FailureR3 Stem Cell
Discover the groundbreaking advancements in stem cell therapy by R3 Stem Cell, offering new hope for women with ovarian failure. This innovative treatment aims to restore ovarian function, improve fertility, and enhance overall well-being, revolutionizing reproductive health for women worldwide.
R3 Stem Cell Therapy: A New Hope for Women with Ovarian Failure
Presentation –Action plan for the health sector response to HIV
1. Action plan for the health
sector response to HIV
Dr Nedret Emiroglu
Director
Health Emergencies and Communicable Diseases
2. HIV is decreasing globally but increasing in Europe
– and remains concentrated in key populations
Estimated new infections (global) and newly diagnosed infections (regional)
20000
40000
60000
80000
100000
120000
140000
160000
1400000
1600000
1800000
2000000
2200000
2400000
2600000
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Global
WHO European
Region
Eastern part of
Region
Western and
central parts of
Region
Sources: ECDC/WHO HIV/AIDS surveillance in Europe 2014; and UNAIDS/WHO global HIV estimates.
2
Global: left scale
Regional: right scale
3. Number of people receiving ART and AIDS rates, 2005-2015
Antiretroviral therapy (ART) coverage remains
inadequate in eastern Europe and AIDS is increasing
Estimated % of
people living with
HIV on ART (2015):
• EECA: 21%
• Global: 46%
0.0
2.0
4.0
6.0
8.0
10.0
12.0
0
200000
400000
600000
800000
1000000
1200000
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
AIDScasesper100000population
ART - Western and central Europe (left scale)
ART - Eastern Europe and central Asia (EECA)
(left scale)
AIDS rate - EECA (right scale)
AIDS rate - Region (right scale)
4. Elimination of mother-to-child
transmission of HIV and syphilis
• Three European countries
successfully validated elimination:
– Armenia: HIV
– Belarus: HIV and syphilis
– Republic of Moldova: syphilis
• Many more countries are preparing
for validation
4
Photos: UNAIDS
5. Alignment with global and regional policies and strategies
New HIV action plan calling for urgent accelerated response
Action plan
development:
• Building on
lessons
learned
• Broad
Region-wide
participatory
process
5
6. Action plan for the health sector response to HIV
• Zero new HIV infections, zero HIV-related
deaths and zero HIV-related
discrimination in a world where people
living with HIV are able to live long and
healthy lives
2030
Vision
• To end the AIDS epidemic as a public
health threat by 2030, within the context
of ensuring healthy lives and promoting
well-being for all at all ages
2030
Goal
Frameworks for action: universal health coverage, the
continuum of services, a public health approach
6
7. Strategic direction 1: Information for focused
action (the “who” and “where”)
Fast-track actions
Know your epidemic and response
Use data to guide focused HIV services and investments along the HIV cascade
of services
Set national targets and milestones, update national strategies
Link HIV strategic information systems with broader health information
systems
Strengthen the HIV response through strong coordination across stakeholders
and involvement of civil society
7
8. Strategic direction 2: Interventions for impact
(the “what”)
Fast-track actions
Define an essential package of interventions for inclusion in the national health
benefit package
Prioritize interventions for key and vulnerable populations
Adopt a “treat all” approach to maximize the prevention benefits of ART
Expand HIV testing approaches to reach those who are unaware of their infection
Eliminate HIV in infants
8
9. Strategic direction 3: Delivering for equity
(the “how”)
Fast-track actions
Implement an essential package of services based on equity and human rights
principles
Implement differentiated care packages for people living with HIV (PLHIV),
based on care needs
Ensure integrated, people-centred and community-based care
Create an enabling policy and legal environment
9
10. Strategic direction 4: Financing for sustainability
(the financing)
Fast-track actions
Finance a sustainable HIV response to achieve the 90-90-90 targets
Monitor health expenditures to reduce cost of drugs and services, remove
health-related financial risk for PLHIV
Strengthen procurement and supply management
Transit from external to domestic HIV financing
10
11. Strategic direction 5: Innovation for acceleration
(the future)
Fast-track actions
Stimulate innovation of technologies, service delivery and models of
collaboration
Encourage HIV service delivery through innovative approaches that are designed
and delivered in collaboration with civil society
Ensure a particular focus on reducing the undiagnosed proportion of PLHIV and
innovative service delivery for key populations
11
12. Draft resolution – EUR/RC66/Conf.Doc./5 Rev.1
• Review and revise national HIV strategies and targets, prioritizing
key populations
• Strengthen HIV prevention by promoting evidence-based
interventions; implement an essential package of services
• Reinforce political commitment and ensure sustainable financing
• Continue working in partnerships to strengthen the HIV response,
and facilitate the exchange of best practices
• Monitor and report to 69th and 72nd Regional Committees on
implementation of the action plan
12
Today we are presenting a new action plan on HIV in Europe for your consideration.
The WHO European Region is at a critical point with regard to HIV. While new HIV infections are decreasing globally, in Europe they are increasing. New HIV diagnoses have increased by 76% since 2005 in the Region as a whole and have more than doubled in the east.
Not only are new infections increasing. The epidemic remains concentrated in key populations, mainly among men who have sex with men (MSM) in the centre and west and among people who inject drugs in the East.
If time permits, consider: Transmission through injecting drug use is declining in most countries, but still accounts for almost half of all new HIV cases with a known transmission mode in the East where MSM related transmission is underreported and stigmatized.
Good news is that more people are receiving antiretroviral therapy (ART) in the Region. The overall number on ART increased from 360 000 in 2005 to about one million in 2015 and almost tripled in the East during the last five years (from 112 100 in 2010 to 321 800 in 2015).
However, in the eastern part of the Region, only an estimated 21% of all people living with HV were receiving treatment in 2015 – well below the global average of 46%. (If time permits: Please note here that newly revised WHO treatment guidelines, that recommend ART to all people living with HIV, has lowered the ART coverage compared with past recommendations where only people with more advanced disease would be eligible for treatment.)
The number of new AIDS diagnoses continue to increase in the eastern part of the Region. This is the result of several factors:
About half of people continue to be diagnosed at a late stage of infection (48% had a CD4 cell count below 350 cells/mm3 at the time of diagnosis in 2014)
In some countries, up to half of people living with HIV are unaware of their infection.
Delayed initiation of ART and low treatment coverage.
FYI/additional: The percentage of people diagnosed late was largest in the eastern part of the Region and smallest in the western part. This is partly explained by the larger numbers of people who inject drugs with HIV in the East who tend to be diagnosed later than people from other transmission groups.
Against this epidemiological situation, we need an urgent and accelerated fast track response to curb the epidemic in the Region.
Another area in which the Region has made excellent progress is towards eliminating mother to child transmission of HIV and congenital syphilis as a public health threat.
Three European countries - Armenia, Belarus and Moldova - were provided with elimination certificates at the High Level Meeting on HIV in New York in June this year. I know many others are working with us towards validating elimination.
We conclude that the HIV epidemic in the European Region is moving faster than the current programmes established to address it, and that a fast track response is required.
The new HIV Action plan advocates for an urgent and accelerated health sector response to HIV and builds on lessons learned from the previous European Action Plan that ended in 2015. The goals and targets in the plan are supported by the 2030 Agenda for Sustainable Development, the 2016-2021 multisectoral UNAIDS Strategy, the WHOs Global health sector strategy on HIV for 2016–2021, and Health 2020, the European policy framework for health and well-being.
The Action plan was developed through a broad Region-wide participatory process including a Regional technical consultation convened in June 2015 and drawing on the expertise of an advisory committee that met in Copenhagen in April 2016. It also sought feedback through direct correspondence with Member States, major partners and people living with HIV, and through a broader public web consultation on the action plan.
The Action plan is built around three organizing frameworks for action: universal health coverage; the continuum of HIV services; and the promotion of a public health approach in accordance with the Global Health Sector Strategy for HIV 2016-21.
Our vision for 2030 is a WHO European Region with zero new HIV infections, zero HIV-related deaths and zero HIV-related discrimination in a world where people living with HIV are able to live long and healthy lives.
Our goal for 2030 is to end the AIDS epidemic as a public health threat in the European Region in the context of ensuring healthy lives and promoting well-being for all at all ages.
Key targets for 2020, contributing towards achieving the 2030 goal proposed in this new action plan focus on:
Strengthening prevention efforts (reducing new infections by 75% or an appropriate numerical target for low-prevalence countries)
Scaling up testing and treatment – the global 90-90-90 targets (90% of people living with HIV know their HIV status; 90% of people diagnosed with HIV receive ART; 90% of people living with HIV on ART achieve viral load suppression)
Reduction of AIDS related deaths
Eliminating discrimination
Ensuring financial sustainability
The action plan is organized around five strategic directions, each with a set of fast track actions for Member States, WHO and partners. The next five slides summarize these fast track actions which are described in more detail on pages 7 through 14 in the RC document EUR/RC66/9.
Strategic direction 1 focuses on the need to generate and use quality strategic information about the HIV epidemic.
Strategic information forms the basis for focused national strategic planning and programme implementation, and advocacy to garner political commitment. It guides Member States to evaluate the health systems’s performance along the HIV continuum of care and develop targeted high-impact programmes and interventions.
Strategic direction 2 describes the delivery of critical, high-impact evidence-based interventions to optimize the continuum of HIV services, including prevention, testing, treatment and care.
This strategic direction encourages countries to specify an essential package of interventions for inclusion in the national health benefit package for people living with HIV or at risk of acquiring HIV.
It focuses on the implementation of interventions contextualized to the local epidemiology and setting, prioritizing interventions aimed at key populations who are disproportionately affected by HIV to ensure that no one is left behind.
Strategic direction 3 responds to the need for an enabling environment and optimization of service delivery.
It focuses on identifying the best approaches for delivering services by promoting integrated, people-centered services and ensuring equity and quality. It also focuses on the involvement of civil society, including people living with HIV, in the design and delivery of interventions.
If time permits: This strategic direction also draws on the years of evidence that shows that HIV interventions are most effective when they occur in enabling social, legal, policy and institutional environments.
Strategic direction 4 urges Member States to develop sustainable and innovative models to finance their HIV response.
This activity is critical as the European Region is facing the withdrawal of funding from international donors. This demands the Region identify domestic resources and efficiency-focused strategies which enable the continued delivery of HIV services in a way that minimises service interruptions and minimises out of pocket expenses for PLHIV.
Strategic direction 5 identifies those areas where there are major gaps in knowledge and technologies. It highlights the areas where innovation is required to shift the course of the HIV epidemic to achieve the 2020 targets and 2030 goal and vision.
Given of much of the HIV-related need in the Region is situated among key and vulnerable populations, Member States focus should be on innovations targeted at these populations.
Accordingly, innovation in the WHO European Region should look to biomedical advancements as well as innovations in communication, behaviour change, service delivery, economic modelling, and engagement strategies for key and vulnerable populations.
The draft Resolution request Regional Committee consider a resolution to adopt the Action plan and urge Member States to:
review and revise national HIV strategies and targets based on the local epidemiology and national context,
prioritize key populations, women and girls, to ensure full access to HIV prevention, testing and treatment services and to remove legislative and structural barriers through intersectoral collaboration and involvement of civil society;
strengthen HIV prevention by promoting high-impact, evidence-based cost-effective comprehensive interventions and innovative tools;
define a package of services for people living with HIV and ensure implementation of a set of interventions, by promoting integrated, people-centred and community-based services to meet treatment coverage targets;
reinforce political commitment and ensure sustainable financing for HIV.
The draft resolution also requests the Regional Director to:
support the implementation of the Action plan through leadership, strategic direction and technical guidance to Member States;
continue work in partnership to advocate for commitment and resources to strengthen the response to HIV;
facilitate the exchange of best practices and evidence-informed tools for an effective HIV response;
monitor implementation and report to the 69th and 72nd sessions of the Regional Committee on the implementation of the Action plan in the WHO European Region.